Overview

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks
Phase:
Phase 3
Details
Lead Sponsor:
Novartis